Anixa Biosciences and Cleveland Clinic to Present More Phase 1 Breast Cancer Vaccine Data at 39th SITC Meeting

SAN JOSE, Calif., Oct. 28, 2024 -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company centered on treating and preventing cancer, has unveiled new data from its Phase 1 clinical trial of a breast cancer vaccine. This information was presented at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, which is being held virtually and in Houston, Texas, from November 6-10, 2024. The clinical trial is a collaborative effort with the Cleveland Clinic and is funded by a grant from the U.S. Department of Defense. Dr. Emily Rhoades, the FDA/IND Trial Program Manager at Cleveland Clinic, delivered the presentation titled "Phase I Trial of alpha-lactalbumin vaccine in high risk operable triple negative breast cancer (TNBC) and patients at high genetic risk for TNBC."

Following the presentation, Anixa will publicize the poster presentation on its website and through a public announcement.

Anixa's breast cancer vaccine harnesses endogenously produced proteins. These proteins function at specific times in life but later become "retired" and vanish from the body. A notable example is a breast-specific lactation protein named α-lactalbumin, which is absent in normal, aging tissues post-lactation but is present in certain breast cancers. By stimulating the immune system against this "retired" protein, the vaccine aims to provide preemptive immune protection against emerging breast tumors expressing α-lactalbumin. The vaccine includes an adjuvant that triggers an innate immune response, enabling the immune system to counteract emerging tumors and prevent their growth.

The initial Phase 1 data, presented at the San Antonio Breast Cancer Symposium in December 2023, indicated no safety concerns, with protocol-defined immune responses observed in the majority of patients.

The Phase 1 trial is being conducted in association with the Cleveland Clinic and funded by a U.S. Department of Defense grant. Anixa holds the exclusive worldwide license for the innovative breast cancer vaccine technology developed at Cleveland Clinic. The U.S. Department of Defense provided grant funding to Cleveland Clinic.

This vaccine technology was conceived by the late Dr. Vincent Tuohy, who held the Mort and Iris November Distinguished Chair in Innovative Breast Cancer Research in the Department of Inflammation and Immunity at Cleveland Clinic's Lerner Research Institute. Cleveland Clinic granted exclusive licensing of this technology to Anixa Biosciences and is entitled to royalties and other commercialization revenues from the company.

Anixa is a clinical-stage biotechnology firm dedicated to cancer treatment and prevention. Its therapeutic portfolio includes an ovarian cancer immunotherapy program in collaboration with Moffitt Cancer Center, utilizing a novel CAR-T technology known as chimeric endocrine receptor-T cell (CER-T) technology. The company's vaccine portfolio features vaccines developed in partnership with Cleveland Clinic to treat and prevent breast and ovarian cancer, along with additional cancer vaccines targeting high-incidence malignancies in the lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins found in specific cancers. Anixa's business model of collaborating with prominent research institutions at all development stages enables the company to continually explore and develop emerging technologies in related fields for further commercialization.